Diagnostic Imaging Devices are used for the visualization of structural and functional patterns of organs or tissues. A Nuclear Imaging agent is a compound, usually based on a drug molecule, that includes a small amount of radioactive material, or radiotracer. Radiotracers emit a signal that can be detected by a Single Photon Emission Computed Tomography (SPECT) camera or a Positron Emission Tomography (PET) camera. GlobalData uses proprietary data and analytics to provide a comprehensive report on the nuclear imaging agents devices market, including market shares of different players within Australia. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the nuclear imaging agents market in Australia was GE HealthCare Technologies followed by Bracco Diagnostics, Lantheus Medical Imaging, Cardinal Health and Advanced Accelerator Applications.
PET Imaging Agents include Copper-Based PET Imaging Agents, Fluorine-Based PET Imaging Agents, Gallium-68-Based PET Imaging Agents and Rubidium-Based PET Imaging Agents. SPECT Imaging Agents includes Indium-Based SPECT Imaging Agents, Iodine-Based SPECT Imaging Agents, Lutetium-Based SPECT Imaging Agents, Technetium-Based SPECT Imaging Agents and Thallium-Based SPECT Imaging Agents.
The value of the nuclear imaging agents devices market within Australia was expected to be over $20m in 2023.
For the latest complete market share analysis of nuclear imaging agents device market in Australia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
